Clinical trial
Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer
NCT00003633 · Herbert Irving Comprehensive Cancer Center, Other · Unknown status
Key facts
| NCT number | NCT00003633 |
|---|---|
| Title | Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer |
| Official title | Treatment of Prostate Cancer by Induction of Alternate Cell Death Pathways: A Phase I Trial of Docetaxel, Estramustine, Mitoxantrone and Prednisone |
| Lead sponsor | Herbert Irving Comprehensive Cancer Center, Other |
| Status | Unknown status |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | docetaxel, estramustine phosphate sodium, mitoxantrone hydrochloride, prednisone |
| Enrollment | 12 |
| Start date | Aug 1, 1998 |
| First posted | Jan 27, 2003 |
| Last update posted | Dec 19, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: